Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24. Materials and methods: Patients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24. Results: Overall, 153 patients were evaluated, and 51 patients (33.3%) achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p < 0.001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population. After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.094). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p < 0.001). Conclusion: Patients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.
Abstract
Purpose: Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24. Materials and methods: Patients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24. Results: Overall, 153 patients were evaluated, and 51 patients (33.3%) achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p < 0.001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population. After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.094). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p < 0.001). Conclusion: Patients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.
참고문헌 (19)
- Marchi E, "The rapidly changing landscape in mature T-cell lymphoma(MTCL)biology and management", CA Cancer J Clin, 70, pp.47~70 (2020)
- Anderson JR, "Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project", Ann Oncol, 9, pp.717~720 (1998)
- Ellin F, "Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas : a study from the Swedish Lymphoma Registry", Blood, 124, pp.1570~1577 (2014)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Mak V, "Survival of patients with peripheral T-cell lymphoma after first relapse or progression : spectrum of disease and rare long-term survivors", J Clin Oncol, 31, pp.1970~1976 (2013)
- Broccoli A, "Peripheral T-cell lymphomas : focusing on novel agents in relapsed and refractory disease", Cancer Treat Rev, 60, pp.120~129 (2017)
- Maurer MJ, "Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy", J Clin Oncol, 32, pp.1066~1073 (2014)
- Shi Q, "Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma : an individual patient-level analysis of multiple randomized trials(SEAL)", J Clin Oncol, 36, pp.2593~2602 (2018)
- Hapgood G, "Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia", J Clin Oncol, 34, pp.2493~2500 (2016)
- Maurer MJ, "Early event status informs subsequent outcome in newly diagnosed follicular lymphoma", Am J Hematol, 91, pp.1096~1101 (2016)
- Maurer MJ, "Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma", Am J Hematol, 91, pp.179~184 (2016)
- Maurer MJ, "International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma", J Clin Oncol, 35, pp.4019~4026 (2017)
- Wudhikarn K, "Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma", Hematol Oncol, 37, pp.578~585 (2019)
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project, "A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
- Gallamini A, "Peripheral T-cell lymphoma unspecified(PTCL-U) : a new prognostic model from a retrospective multicentric clinical study", Blood, 103, pp.2474~2479 (2004)
- Kim YR, "Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification", Ann Hematol, 93, pp.1867~1877 (2014)
- Vose J, "International peripheral T-cell and natural killer", T-cell lymphoma study : pathology findings and clinical outcomes, 2008, pp.26, 4124~4130
- Casulo C, "T-cell lymphoma: recent advances in characterization and new opportunities for treatment", J Natl Cancer Inst, 109, pp.djw248~ (2017)
- Savage KJ, "ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified : report from the International Peripheral T-Cell Lymphoma Project", Blood, 111, pp.5496~5504 (2008)